About NBR“Nightly Business Report produced by CNBC” (NBR) is an award-winning and highly-respected nightly business news program that airs on public television. Television’s longest-running evening business news broadcast, “NBR” features in-depth coverage and analysis of the biggest financial news stories of the day and access to some of the world’s top business leaders and policy makers.
- A tight labor market is holding small businesses back from expanding in this hot economy
- Netflix should take a cue from 'Game of Thrones' and ditch binge-watching for new shows
- These 8 high-paying work-from-home jobs all pay as much as $90,000 a year or more
- It costs $76,623 to go to Dartmouth—here's how much students actually pay
- Uber, Lyft and Pinterest prove that private investors are sucking up all the value
NBR on TwitterMy Tweets
Subscribe to RSS
44 states have now filed a lawsuit accusing pharmaceutical companies of inflating generic drug prices. Meg Tirrell has more with this story.
We speak with Chris Meekins, a research analyst at Raymond James, about the high cost of drugs in the market today. How can folks afford these expensive drugs?
There’s a new drug that’s worth $2M – the biggest price tag ever – and some are saying this gene therapy drug is worth it. Meg Tirrell has more.
Health researchers say there’s little evidence to show that recent progress is a result of the White House’s efforts. They noted that prescriptions have been declining since 2012, before Trump became president.
Outgoing FDA chief Scott Gottlieb releases a much-anticipated draft policy restricting e-cigarette sales to curb an “epidemic” of teen use.
U.S. Surgeon General Jerome M. Adams declared e-cigarette use among kids an “epidemic” in the U.S. on Tuesday, pointing to companies like Juul as problematic.
Two-thirds of Americans want an independent body to oversee prescription drug pricing.
Almost 1 in 5 rural counties in the U.S. saw increases in the number of premature deaths over the past decade — even as most large urban counties saw regular improvements in their premature death rates.
America’s addiction to prescription painkillers is taking a big toll on the workplace. Is enough being done by companies to get it under control?
Over the next couple of weeks two drugs that combat a rare and fatal form of muscular dystrophy will come under review, in what could be a watershed moment for patients.
Insys Therapeutics CEO Michael Babich has stepped down, with company chairman Dr. John Kapoor taking over as CEO. The news comes as the company reported third quarter earnings on Thursday, and shortly after CNBC released an investigative piece on Wednesday on the company, which included allegations of fraud, kickbacks, and aggressive drug marketing behavior by …
Washington’s leading liberal think tank is talking about doing something to control rising drug prices, but will the next president and Congress listen? The Center for American Progress—whose founder John Podesta is now chairing Hillary Clinton’s presidential campaign—on Friday called for a series of steps to address what it called “this growing crisis” of prescription …
Gilead said in its earnings report that it gave insurers steeper-than-expected discounts on its hepatitis C drugs.
The President is asking millions to fund a new medical research initiative and he met with the country’s biggest drugmakers to discuss the details of his plan.
FedEx has been indicted on 15 criminal counts for helping internet pharmacies deliver drugs to buyers in the U.S. without prescriptions.